Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CStone Pharmaceuticals
Biotech
Geopolitics threatens Chinese biotechs' hot out-licensing biz
For the first time, China biotechs out-licensed more assets in 2023 than they in-licensed.
Max Bayer
Apr 11, 2024 4:00am
EQRx abandons low cost drug plan, cuts programs and staff
May 8, 2023 7:19pm
Striking deals with Blueprint COO Haviland
Sep 22, 2021 10:10am
You want discount drugs? EQRx wants $1.8B first via SPAC deal
Aug 6, 2021 10:50am
Former Sanofi exec joins $750M-funded EQRx to lead drug creation
Jul 1, 2021 10:05am
Phase 3 data boost EQRx's plan to undercut checkpoint inhibitors
May 28, 2021 8:15am
